Singapore markets closed

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
43.44+0.54 (+1.26%)
At close: 04:00PM EDT
43.60 +0.16 (+0.37%)
After hours: 06:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close42.90
Open43.13
Bid40.00 x 200
Ask47.01 x 200
Day's range43.13 - 43.60
52-week range19.59 - 43.61
Volume2,172,718
Avg. volume1,641,614
Market cap7.915B
Beta (5Y monthly)1.41
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease

    Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with placebo over 27 weeks Results demonstrate tavapadon’s potential to provide the right balance of motor control, safety and tolerability for people living with Parkinson’s disease Additional data from the trial will be presented at a future medical meeting; results from the tavapadon Phase 3 monotherap

  • PR Newswire

    AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline

    AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) today announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson's disease (PD), and mood disorders. The acquisition complements AbbVie's neuroscience portfolio, adding a wide range of potentially best-in-class assets that may transform standa

  • GlobeNewswire

    Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson’s Disease

    Event will focus on tavapadon, a D1/D5 partial agonist in Phase 3 development for the treatment of Parkinson’s disease Live webcast scheduled for Monday, December 11 from 10:00 to 11:30 a.m. ET CAMBRIDGE, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host a tavapadon investor webcast on Monday, December 11, from 10:00 to 11:30 a.m. ET. Cerevel will lead a